Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Current Assets (2020 - 2025)

Maxcyte (MXCT) has disclosed Current Assets for 6 consecutive years, with $124.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Assets fell 27.91% to $124.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $124.6 million, a 27.91% decrease, with the full-year FY2024 number at $171.7 million, down 9.73% from a year prior.
  • Current Assets was $124.6 million for Q3 2025 at Maxcyte, down from $143.2 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $270.4 million in Q4 2021 to a low of $84.6 million in Q2 2021.
  • A 5-year average of $203.5 million and a median of $202.3 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: skyrocketed 497.6% in 2021, then dropped 27.91% in 2025.
  • Maxcyte's Current Assets stood at $270.4 million in 2021, then decreased by 6.72% to $252.3 million in 2022, then dropped by 24.61% to $190.2 million in 2023, then fell by 9.73% to $171.7 million in 2024, then dropped by 27.4% to $124.6 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Current Assets are $124.6 million (Q3 2025), $143.2 million (Q2 2025), and $155.7 million (Q1 2025).